BORSA: Stock News & AlertsFree on the App StoreFree on Google PlayGet Get

BORSAStock News & Alerts

Latest News Calendar Reports Stocks Sign in

BORSAStock News & Alerts

Latest News Calendar Reports Stocks Sign in

Unlock full report

SPY−1.15%$762.91QQQ−2.41%$710.46

TSLA−2.91%$351.89AAPL+0.27%$342.92NDAQ−0.36%$93.16SPCX−3.10%$144.01BKR+2.15%$55.57NVDA−0.93%$215.22TFC+1.75%$47.39LRCX−4.28%$265.58TOL−0.69%$133.02CBOE+2.13%$314.64SHOP−5.38%$168.55GPRK+2.25%$11.79PSX+1.33%$293.04B+0.15%$40.61SMTC−4.50%$137.73LMT+3.21%$549.73EFX−0.41%$160.60XOM+2.10%$178.35MSTR−10.13%$135.97DKNG−3.42%$18.65GS−1.24%$880.22ROKU−0.39%$154.07UNH−1.14%$402.03NFLX−3.25%$70.25MU−4.88%$885.80HPE−5.43%$55.45TWLO−11.08%$243.11C+0.63%$123.99JNJ+0.81%$255.34SCHW−2.53%$91.78TSLA−2.91%$351.89AAPL+0.27%$342.92NDAQ−0.36%$93.16SPCX−3.10%$144.01BKR+2.15%$55.57NVDA−0.93%$215.22TFC+1.75%$47.39LRCX−4.28%$265.58TOL−0.69%$133.02CBOE+2.13%$314.64SHOP−5.38%$168.55GPRK+2.25%$11.79PSX+1.33%$293.04B+0.15%$40.61SMTC−4.50%$137.73LMT+3.21%$549.73EFX−0.41%$160.60XOM+2.10%$178.35MSTR−10.13%$135.97DKNG−3.42%$18.65GS−1.24%$880.22ROKU−0.39%$154.07UNH−1.14%$402.03NFLX−3.25%$70.25MU−4.88%$885.80HPE−5.43%$55.45TWLO−11.08%$243.11C+0.63%$123.99JNJ+0.81%$255.34SCHW−2.53%$91.78

After Hours ReportWed, Aug 197:30 PM ETLate-session wrap

Moderna and Merck personalized mRNA cancer vaccine succeeds in Phase 3 melanoma trial

Moderna and Merck reported their personalized mRNA cancer vaccine succeeded in a Phase 3 trial for melanoma. AI reportedly helped design the vaccine. 43 clean stories shaped this window, with sentiment neutral at 52/100. Also in focus: Merck and Moderna report positive Phase 3 result for personalized cancer vaccine.

Sentiment52/100 · Neutral

Market readNeutralat publication

Stories43clean stories in the window

Published7:30 PMWed, Aug 19 · ET

Stories that shaped this window

ranked headlines are open · briefs and the tape open with a free account (3 a day) or BORSA Plus

01

Corporate Action$MRNA

Moderna and Merck personalized mRNA cancer vaccine succeeds in Phase 3 melanoma trial

02

Earnings$MRNA $MRK

Merck and Moderna report positive Phase 3 result for personalized cancer vaccine

Reports are fixed publication-time snapshots of news-derived sentiment. Information only, not investment advice.

News Calendar Reports Stocks Sign in

03

Earnings$WOLF

Wolfspeed Q4 revenue $149.6M misses $224M estimate, guides $140M-$160M

04

Macro

US 30-Year Treasury Yield Hits 5.30%, Highest Since 2007

FREE ACCOUNT · 3 COMPLETE REPORT VIEWS A DAY

The ranked headlines are open. The briefs and the market tape open with a free account.

One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.

MARKET TAPE•• indices · •• sectorsPrice and breadth at publication

COMPANY CONTEXT•• analyzed namesEarnings, guidance and ownership

EDITOR'S READ••••••••••What changed and what comes next

FULL BRIEFS•• developmentsEvery ranked story, written out

BORSAPLUSFull briefs · Market tape at publication · Company context · Editor's read

Create a free account · no card →

the wire stays free to read · BORSA Plus removes the daily limit: start 3 days free, then $49.99 a year or $9.99 a month →

Three complete report and ticker views a dayfree account

Create a free account to open the full briefs and the market tape behind three reports or tickers each day, with every story, the live board and the 30-day calendar open. BORSA Plus removes the daily limit.

Create a free account · no card →

Reports are fixed publication-time snapshots of news-derived sentiment. Information only, not investment advice.